The implant is engineered to offer PER-001’s sustained release, aiming for a “convenient” dosing frequency of every six months.

Despite advances in anticoagulant therapies, bleeding remains a critical concern.Traditionally, the definition of major ...

The bio-erodible implant is administered into the eye’s vitreous cavity with a 25-gauge applicator. Credit: elenavolf / Shutterstock. Perfuse Therapeutics has reported 24-week data from its ...

Perfuse Therapeutics has reported 24-week data from its first-in-human, multi-centre Phase I/IIa trial of the PER-001 intravitreal implant for individuals with glaucoma. The trial of PER-001 is ...

A new study reveals that encapsulated heating methods, an often-used heat simulation method, significantly increase heart rates and cardiac strain compared to natural heat exposure like those ...

14.0 35.6 59.1 (23.5) - ST / 1000 m / tf / 9 bt 10 / H Bowman / Swimming ...

Twenty-four-week data from the Ph1/2a trial in glaucoma patients reveals PER-001 to be well-tolerated. Proof of concept is established with both strong functional and structural outcomes Glaucoma ...

PNC Financial Services Group Inc. trimmed its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 4.1% during ...

Alongside the approval, RetinaLogik closed a C$1.1m funding round to expand the adoption rate of its technology.

It's on the last of those streaming services that The Electric State will attempt to arrest that slide. Unfortunately, ...